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Background: Dihydroartemisinin-piperaquine (DhP) is highly recommended for the treatment of uncomplicated
malaria. This study aims to compare the costs, health benefits and cost-effectiveness of DhP and artemether-lumefantrine
(AL) alongside “do-nothing” as a baseline comparator in order to consider the appropriateness of DhP as a first-line
anti-malarial drug for children in Tanzania.
Methods: A cost-effectiveness analysis was performed using a Markov decision model, from a provider’s perspective. The
study used cost data from Tanzania and secondary effectiveness data from a review of articles from sub-Saharan Africa.
Probabilistic sensitivity analysis was used to incorporate uncertainties in the model parameters. In addition,
sensitivity analyses were used to test plausible variations of key parameters and the key assumptions were tested
in scenario analyses.
Results: The model predicts that DhP is more cost-effective than AL, with an incremental cost-effectiveness ratio
(ICER) of US$ 12.40 per DALY averted. This result relies on the assumption that compliance to treatment with
DhP is higher than that with AL due to its relatively simple once-a-day dosage regimen. When compliance was
assumed to be identical for the two drugs, AL was more cost-effective than DhP with an ICER of US$ 12.54 per
DALY averted. DhP is, however, slightly more likely to be cost-effective compared to a willingness-to-pay threshold of US$
150 per DALY averted.
Conclusion: Dihydroartemisinin-piperaquine is a very cost-effective anti-malarial drug. The findings support its use as an
alternative first-line drug for treatment of uncomplicated malaria in children in Tanzania and other sub-Saharan African
countries with similar healthcare infrastructures and epidemiology of malaria.
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Disability adjusted life yearsBackground
Malaria is an infectious disease which disproportionately
affects pregnant women and children under the age of
five years, and the disease is a major health problem
in sub-Saharan Africa. In 2012, an estimated 627,000
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accounts for 3.3% (82,685,000) of all Disability Adjusted
Life Years (DALYs) and is ranked seventh among the
top leading causes of DALYs globally [2]. Over the years,
countries in sub-Saharan Africa have repeatedly changed
their treatment policies in response to parasite resistance
to monotherapy anti-malarials [3]. Recently, more ex-
pensive artemisinin-based combination therapy (ACT)
has been recommended and have become increasingly
common as first-line regimens against Plasmodium fal-
ciparum malaria [1,3].d. This is an Open Access article distributed under the terms of the Creative
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Figure 1 State-transition diagram of the model.
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mends several artemisinin-based combinations for
the treatment of uncomplicated malaria, including
artesunate-sulphadoxine-pyrimethamine (ASSP), artesunate-
amodiaquine (ASAQ), artesunate-mefloquine (ASMQ),
artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine (DhP) [4]. The newest ACT on this list is
DhP, which has been proved to be more effective [5,6],
but is unfortunately also more expensive than AL,
which is currently the most commonly used ACT in
sub-Saharan Africa. Despite being more expensive,
DhP has been recommended as a first-line or second-line
alternative treatment for uncomplicated malaria [7-13].
In 2007, Tanzania changed its malaria treatment guide-
lines and adopted the use of AL as the first-line treat-
ment for uncomplicated P. falciparum malaria to replace
SP [14]. In 2013, the standard treatment guidelines were
updated and DhP was officially adopted as the second-
line drug for uncomplicated malaria [15]. AL has been
shown to be a highly cost-effective first-line drug for the
treatment of uncomplicated malaria [16,17], but the
cost-effectiveness evidence for DhP compared to AL is
very limited [18].
Several countries in sub-Saharan Africa have officially
adopted the use of DhP for the treatment of uncompli-
cated malaria [19,20], and many others in the region are
also contemplating this change. New drugs are typically
more expensive than the existing alternatives: hence
good trial results alone should not guarantee their inclu-
sion in treatment guidelines as the additional health
benefits may not be worth the extra costs. Pharmacoeco-
nomic analyses are increasingly being used to generate
evidence for decision-making in developing countries
[21]. Therefore, this study aims to compare the costs,
health benefits and cost-effectiveness of DhP and AL
alongside “do-nothing” as a baseline comparator in order
to consider the appropriateness of DhP as a first-line
anti-malarial drug for children in Tanzania.Methods
Decision model
Cost-effectiveness was analysed using a Markov decision
model with four mutually exclusive health states: “well”,
“uncomplicated malaria”, “severe malaria” and “death”
(Figure 1). Newborn children are assumed to be pro-
tected from malaria through breastfeeding, and enter the
model when they are six months old in a “well” state. In
the model, they are tracked until they are five years old,
after which they are assumed to have gained sufficient
clinical immunity against malaria [22,23]. During this
time, children move between the health states in one-
week cycles depending on risk factors, access to and ef-
fectiveness of anti-malarial treatments.The model assumes that children first develop uncom-
plicated malaria, from which they may recover and re-
turn to the “well” state, or they may progress to “severe
malaria”, which requires hospitalization. “Death” is an
absorbing health state, which may occur spontaneously
(i.e. background mortality) or as an outcome of severe
malaria. In each cycle the model captures and accumu-
lates costs and utilities related to the patient’s health
state. Probabilistic Sensitivity Analyses (PSA) were based
on a Monte Carlo simulation with 10,000 iterations
using TreeAge Pro© 2014 software.
Collection of cost data
Cost data from a provider’s perspective was collected at
Mwananyamala Hospital in Dar- es Salaam region, from
August to November 2012. This is an urban, district-
level public hospital with about 400 beds and 400,000
visits per year. Costs were collected for the treatment of
both uncomplicated and severe malaria in order to cap-
ture the additional costs for patients who develop severe
malaria after unsuccessful treatment with the first-line
drugs. A district hospital was chosen because it is the
lowest level at which severe malaria can be managed ef-
fectively within the Tanzanian healthcare system. Costs
represent the expenditures incurred during the financial
year that ended on June 30th 2012 and were collected
using an ingredient approach [24]. Costs were collected
in the local currency and converted to US dollars (US$
1 = 1,578 Tanzanian shillings) [25].
Four service centres were identified; namely the general
outpatient department, general paediatric ward, pharmacy
and the laboratory. Support departments, which included
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as overheads. Costs for resources which last longer than a
year were categorized as capital costs and included furni-
ture, equipment and motor vehicles. Recurrent costs were
those incurred on resources that are purchased regularly
and used up in the course of a year, and include salaries
rental charges, utilities and supplies [26].
Cost data were recorded in a pre-tested questionnaire
which was designed to capture all the necessary data, in-
cluding the types and quantities of items, their sources,
prices and allocation base. Functioning capital items
were identified, counted and valued using their assumed
replacement market prices. The price catalogue from the
Medical Stores Department (MSD) was used to value
medical items and supplies [27]. Capital costs were
annuitized at a discount rate of 12% as recommended by
the Bank of Tanzania [25] and their useful life years were
adopted from the WHO-CHOICE Project [28].
Staff members were identified and interviewed in
order to discover their monthly earnings, including
gross salary and other standard remunerations. Salary
scales and remunerations were cross-checked and vali-
dated by the hospital secretary. Personnel costs attrib-
utable to malaria were calculated by multiplying total
staff monthly earnings by the percentage of their
time devoted to malaria. For the buildings, floor
spaces were measured and valued as per the square
metre rental charges recommended by the National
Housing Corporation.
The Global Fund’s maximum manufacturer prices for
ACTs that are financed through the Affordable Medi-
cines Facility-malaria (AMFm) was used to estimate the
mean cost of a course of treatment with AL and DhP
[29]. For AL the “6×2” tablet pack specified for children
weighing 15–24 kg was used [13] and the “3×1” tablet
pack for children weighing 13–24 kg was used for DhP
[30]. These prices were inflated by 10% to account for
freight and insurance costs [31] and further by a domes-
tic margin factor of 1.43 to represent local opportunity
costs [32]. Prices of all the other drugs used in the man-
agement of malaria were taken from the MSD’s Price
Catalogue.
Each service department was allocated a portion of
the overhead costs proportional to its percentage con-
tribution to the total allocation base by using the
direct-allocation method [24]. For example, cleaning
costs were allocated based on floor space. Allocation
was difficult for some expenditure, such as electricity,
medical supplies, stationery, which were paid for cen-
trally but for which usage was not specified by the de-
partments. Therefore, some of the overhead costs were
equally distributed between the departments while
others were allocated using an estimated weighted-
allocation factor based on interviews with hospitalmanagement. For more details about personnel costs
and rental charges, see Additional file 1.
The hospital has Health Management and Informa-
tion System (HMIS) tools to keep records of all the at-
tendances and diagnoses made during each year.
However, because of poor recording, the attendances
of malaria patients in the pharmacy or the laboratory
could not be tracked. Therefore, the unit costs for the
treatment of uncomplicated and severe malaria were
calculated by dividing the total costs attributable to
malaria for the service centres by the respective num-
ber of outpatients (7,076 cases) and hospitalized pa-
tients (1,263 cases) recorded in the HMIS tools during
the year.
Choice of health outcomes
Disability Adjusted Life Years (DALYs), which com-
bines years of life lost due to premature death (YLL)
and years of life lived with disabilities (YLD), was used
as a measure of health outcomes [2]. Disability weights
of 0.005 and 0.21 for mild and severe acute episodes of
infectious diseases from the recent Global Burden of
Disease study were applied for uncomplicated and se-
vere malaria, respectively [33]. DALYs averted were
calculated using standard methods [34] as a difference
of DALYs lost with and without the intervention, based
on a life expectancy of 57 years at age 5 for Tanzania
[35]. Base case DALYs were discounted at 3%, without
age-weighting. Results for age-weighted and undis-
counted DALYs were reported in the scenario analysis.
Interventions compared
The study compares DhP (the potential new standard
of care) and AL (the existing standard of care) along-
side “do nothing” as a baseline comparator. Both drugs
are administered for three consecutive days, but AL
should be given twice a day with high-fat meals [36]
while DhP is given once a day without the requirement
for fatty meals [37]. Because of its relatively simple
dosage regimen, it is likely that compliance with and
hence the effectiveness of DhP will be higher than that
of AL in clinical settings. DhP also offers a longer pa-
tient protection from re-infection with malaria because
piperaquine has a significantly longer elimination half-
life of 3–4 weeks compared to the 4–6 days of lume-
fantrine [38]. The impact of high compliance with DhP
is included in the base-case scenario of our model,
while that of longer protection is not.
Measurement of effectiveness
Patient compliance to treatment in routine clinical prac-
tice plays a key role in the effectiveness of anti-malarial
therapies. Thus the effectiveness of each drug, Eff, was
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using the equation below:
Eff ¼ EoC þ Enc 1‐ Cð Þ
Where Eo is the efficacy, C is the compliance rate and
Enc is the proportion of non-compliers for whom treat-
ment is effective, assumed to be 10–30%, which has been
employed in several other cost-effectiveness studies for
ACT [39-41]. Efficacy data were extracted from a
large, head-to-head, randomized clinical trial which was
conducted among 6–59-month-old children in seven
African countries with different malaria endemicities:
Uganda, Zambia, Mozambique, Rwanda, Nigeria, Gabon
and Burkina Faso. The study used the 28-day PCR-
corrected cure rate of 97.3% for DhP and 95.5% for AL,
from the intention-to-treat analysis [13].
Evidence on compliance to ACT is very limited and di-
verse [42,43]; however, it has been reported that compli-
ance to AL by “verified timely completion” ranges from
38 to 65% [43]. DhP is a new drug and evidence on its
compliance is currently lacking. Since the potential
benefit of its once-a-day dosage regimen consisting of
only a few tablets is an improved compliance, a range of
60 to 80% was assumed in the base case analysis. This is
a conservative assumption, considering that a compli-
ance of 67–87% and 87.2–92.5% have been reported for
co-blistered and fixed-dose ASAQ, among children in
Tanzania and Madagascar, respectively [44,45]. ASAQ
has a once-a-day dosing schedule similar to that of DhP.
An assumed compliance similar to that of AL was ex-
plored in a scenario analysis.
Transition probabilities
Children enter the model in a “well” state, and can
develop febrile episodes based on the estimated age-
specific incidence rates shown in Table 1. All febrile
children were assumed to be taken to the hospital for
diagnosis, and 10.5% of the episodes were attributed to
malaria [46]. Between 40 and 60% of children with un-
complicated malaria were assumed to have access to
first-line drugs and the probability of cure depends on
efficacy and compliance with treatment. Efficacies of AL
and DhP were 95.5% and 97.3%, [13] and the base line
compliance rates ranged between 38–65% for AL [43]
and 60–80% for DhP. The remaining children were as-
sumed to be treated with over-the-counter non-ACT
anti-malarials, with effectiveness ranging from 40 to
60% [47,48].
In the “do-nothing” arm, between 3–7% of uncompli-
cated malaria cases progress to severe malaria [40],
which has been estimated to have a case fatality rate ran-
ging from 45 to 80% [51]. Between 10 to 20% of the
uncomplicated malaria cases were assumed to recoverspontaneously without treatment. In the DhP and AL
arms, about 3–7% of the uncomplicated malaria cases
progress to severe malaria in the event of treatment fail-
ure [41], of whom between 72–88% were assumed to
have prompt access to inpatient care [53], which reduces
case-fatality rate to 10.9% [52]. Besides malaria, children
can also die of other causes at any state in the model
based on adjusted age-specific probabilities of death
taken from the Tanzanian Life Table [35].Sensitivity and specificity of the test
Bayesian method was used to incorporate the sensitiv-
ity and specificity parameters of the microscopic test
in the model, which have been estimated to be 71.3%
(95% CI: 68.8–73.9) and 92.8% (95% CI: 91.3–94.3),
respectively [56]. Rate of adherence by clinicians to
negative test results was estimated to range from 40 to
60% [56].Model simplifications
The model is a simplification of a complex disease with
complex treatment-seeking behaviour and manage-
ment practices. It is based on the following simplifying
assumptions:
 A child cannot move directly from a “well” to
“severe malaria” state, but severe malaria is always
a progression from uncomplicated malaria.
 Uncomplicated malaria is not fatal, hence a child
cannot move from “uncomplicated malaria” to the
“death” state, except for deaths caused by other
reasons (i.e. background mortality).
 In the event of treatment failure, patients with
uncomplicated malaria will repeatedly use the
same first-line drug, which we assumed will still
be effective.Uncertainty and sensitivity analyses
Uncertainties in parameters were included in the model
by using probability distributions (Table 1). Maximum
and minimum values for each parameter were taken
from the literature and when these were not available,
the mean values were varied by +/− 20% and efficacy
data by +/− 2.5%. The gamma distribution was used to
constrain costs on the [0,+∞] interval and the beta dis-
tribution to fix the probabilities on the [0,1] interval.
Gamma and beta distributions were calculated using the
method of moments [57]. Uncertainty in the PSA results
is presented using a cost-effectiveness acceptability curve
(CEAC). Sensitivity and scenario analyses were also per-
formed to assess the influence of variations in the key
parameters.
Table 1 Parameters used in the economic model and their distributions
Parameters Estimates Distributions Sources
Age-specific probabilities of death
Probability of dying between 0 and 1 year 0.0684 ± 20% Beta [35]
Probability of dying between 1 and 5 years 0.0424 ± 20% Beta [35]
Malaria-attributed deaths in under fives 11% Point estimate [49]
Weekly incidences of fever episodes per child
Less than 12 months 0.106 ± 20% Beta [50]
Age 12–23 months 0.144 ± 20% Beta [50]
Age 24–35 months 0.105 ± 20% Beta [50]
Age 36–47 months 0.087 ± 20% Beta [50]
Age 48–59 months 0.06 ± 20% Beta [50]
Case fatality rates and other probabilities
Untreated severe malaria 60 (45–80%) Beta [51]
Treated severe malaria 10.9% Beta [52]
Early treatment failure leads to severe malaria 5 (3–7%) Beta [41]
Untreated malaria becomes severe 5 (3–7%) Beta [40]
Spontaneous recovery from uncomplicated malaria 15 (10–20%) Beta Assumed
% of febrile episodes attributed to malaria 10.5 ± 20% Beta [46]
% of severe cases with access to inpatient care 80 ± 20% Beta [53]
% of uncomplicated cases with access to AL 50 (40–60%) Beta Primary data
Costs of treating malaria, by severity (US$/case)
Uncomplicated malaria 6.81 ± 20% Gamma Primary data
Severe malaria 76.46 ± 20% Gamma Primary data
Drug costs (US$ per dose)
DhP: 40 mg Dh, 320 mg P (“3×1” pack) 1.46 ± 20% Gamma [29]
AL: 20 mg A, 120 mg L (“6×2” pack) 1.31 ± 20% Gamma [29]
Quinine Injection, 300 mg/ml (2 ml ampoule) 2.15 ± 20% Gamma [27]
Diazepam Injection, 5 mg/ml (2 ml ampoule) 0.23 ± 20% Gamma [27]
Diclofenac Injection 25 mg/ml (3 ml ampoule) 0.20 ± 20% Gamma [27]
Dextrose 5% (500 ml bottle) 4.75 ± 20% Gamma [27]
Ferrous Sulphate + Folic acid, 200 + 0.25 mg 0.30 ± 20% Gamma [27]
Paracetamol Syrup 120 mg/5 ml 0.26 ± 20% Gamma [27]
Efficacy and compliance rates (%)
Efficacy of DhP 97.3 ± 2.5% Beta [13]
Efficacy of AL 95.5 ± 2.5% Beta [13]
Effectiveness of non-ACT anti-malarials 50 (40-60%) Beta [47,48]
Compliance with AL 51 (38–65%) Uniform [43]
Compliance with DhPa 70 (60–80%) Uniform Assumed
Compliance with DhPb 51 (38–65%) Uniform Assumed
Non-compliers with ACTs who are cured 20 (10–30%) Beta [39-41]
Other parameters
Disability weight for uncomplicated malaria 0.005 (0.033–0.081) Beta [33]
Disability weight for severe malaria 0.21 (0.139–0.298) Beta [33]
Discount rate 3% Point estimate [54]
Decision threshold (US$ per DALY averted) 150 Point estimate [55]
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Table 1 Parameters used in the economic model and their distributions (Continued)
Life expectancy at age 5 years 57 Point estimate [35]
Sensitivity of Microscopy 71.3 (68.8–73.9%) Beta [56]
Specificity of Microscopy 92.8 (91.3–94.3%) Beta [56]
aUsed in the base case analysis, bUsed in the scenario analysis.
Mori et al. Malaria Journal 2014, 13:363 Page 6 of 13
http://www.malariajournal.com/content/13/1/363Cost-effectiveness threshold
An intervention that produces more health benefits at a
lower cost than the comparator is considered to be
“strongly dominant” and cost-effective. If it is more
costly but also more effective, it is considered cost-
effective only when its incremental cost-effectiveness ra-
tio (ICER) is less than the willingness-to-pay threshold.
“Extended dominance” occurs when the ICER of an
intervention is higher than that of the next most effect-
ive option [58]. A willingness-to-pay threshold of US$
150 per DALY averted, which has been recommended as
a cut-off point for low- and middle-income countries
was applied [55].
Ethics statement
This study was approved by the Ethical Review Committee
of the Tanzania National Institute of Medical Research withTable 2 Unit costs (US$) for outpatient and inpatient care
Out-patient care for uncomplicated malaria
Service centres
Cost category Items Outpatient
Recurrent Antimalaria drugs -
Other drugs
Personnel 22,988







Inpatient care for severe malaria
Cost category Items Paediatric ward
Recurrent Drugs -
Personnel 75,895






Total unit costsclearance certificate no: NIMR/HQ/R.8a/Vol.IX/1362. The
District Medical Officer in charge of Kinondoni and the
management at Mwananyamala Hospital also gave permis-
sion to conduct the costing study. The interviewed health
workers each provided written informed consent to partici-
pate in the study.Results
Unit costs of treatment
Table 2 presents the estimated unit costs of treating
cases of uncomplicated and severe malaria with the as-
sociated co-morbidities at an urban district-level hospital
in Tanzania. For uncomplicated malaria, the cost per
episode was US$ 8.40 with AL and US$ 8.54 with DhP.
For severe malaria, the hospitalization cost per episode
was estimated to be US$ 83.86.Cost Unit costs
Pharmacy Laboratory Total AL DhP
- - - 1.31 1.46
0.26 0.26
7,748 6,066 36,802 5.20 5.20
538 1,647 3,316 0.47 0.47
1,368 1,539 4,440 0.63 0.63
699 1,558 2,957 0.42 0.42
89 108 228 0.03 0.03
25 25 121 0.02 0.02
109 69 340 0.05 0.05
8.40 8.54
Pharmacy Laboratory Total Unit costs
- - - 7.40
1,202 845 77,942 61.71
717 305 9,034 7.15
494 285 4,559 3.61
162 288 2,715 2.15
21 20 482 0.38
3 5 465 0.37
39 13 1,371 1.09
83.86
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Table 3 presents the base-case analysis, for which the
model predicts that DhP is more cost-effective than AL,
with an ICER of US$ 12.40 per DALY averted. AL was
eliminated in the base-case analysis because it was ex-
tendedly dominated by DhP, therefore, the base-case
ICER value represents the comparison of DhP to a do
nothing strategy. In the scenario assuming a lower com-
pliance, similar to that of AL, ranging from 38–65%, AL
was more cost-effective than DhP with an ICER of US$
12.54 per DALY averted versus US$ 101.52 per DALY
averted.
Incremental cost-effectiveness scatter plot
Figure 2 shows the base-case ICE scatter plot of DhP
versus AL. The model predicts that DhP is cost-effective
in 97% of the simulations and dominated by AL in 2% of
the simulations, at a willingness-to-pay threshold of US$
150 per DALY averted. With a compliance of 38–65%,
DhP was cost-effective in 51% of the simulations and
dominated by AL in 37% of the simulations.
Cost-effectiveness acceptability curve
Figure 3 shows the cost-effectiveness acceptability curves
(CEAC) for the base-case and scenario analyses of DhP
compared to AL. For the base-case, the probability of
DhP being cost-effective was 97% at the willingness-to-
pay threshold of US$ 150 per DALY averted. In the sce-
nario analysis where we assumed the compliance with
DhP to be 38–65%, the probability of DhP being cost-
effective was 51% compared to 49% for AL at the same
willingness-to-pay threshold of US$ 150 per DALY
averted
Characterizing uncertainty
One-way sensitivity analyses were conducted to assess
the influence of plausible variations of key parameters
on cost-effectiveness of DhP versus AL. The result
shows that the cost-effectiveness of DhP relies on the as-
sumption that it has a higher compliance rate than AL,
for which the evidence is weak. This is illustrated in
Figure 4, which shows that when the compliance with
DhP is assumed to be less than 50% it produces fewer
health benefits at higher costs than AL (strongly domi-
nated) and at between 50 and 56% it is less cost-effective
than AL. When compliance exceeds a threshold of 57%,
DhP becomes the cost-effective strategy by extendedTable 3 Base-case cost-effectiveness analysis
Strategy Cost (US$) DALYs Incremental co
No treatment 0.00 17.60 0.00
AL 165.42 4.47 165.42
DhP 166.22 4.22 0.80dominance. Above 85%, DhP produces more health
benefits at a lower cost than AL (strong dominance).
Note that the compliance rate for AL was held
constant at 51%.
Figure 5 shows a tornado diagram which ranks the pa-
rameters in the order of their decreasing influence on
the base-line ICER value. In the diagram, DhP was com-
pared to “do-nothing” because AL was eliminated in the
analysis due to extended dominance. Uncertainties in
parameters describing the natural history of malaria
were the most influential on the ICER value. This in-
cludes the probability of progression to severe malaria
(Untreated to SM), case fatality rate for severe malaria
(CFR untreated SM) and the probability of “self-limiting”
uncomplicated malaria. The cost-effectiveness of DhP
increases with an increase in the values of the first two
parameters but decreases with an increase in the prob-
ability of self-limiting malaria. The cost-effectiveness of
DhP also increases with an increase in the incidence
rates of malaria, making it a good choice in high-
transmission areas.
Two-way sensitivity analysis
The existing evidence for compliance with AL is very di-
verse. We therefore performed a two-way sensitivity ana-
lysis (Figure 6), to determine various combinations of
compliance rates at which the two drugs were cost-
effective, at a willingness-to-pay threshold of US$ 150
per DALY averted. This shows that even when compli-
ance is perfect for both drugs, DhP remains slightly
more cost-effective than AL.
Impact of age-weighting and discounting
In the base-case analysis, DALYs were calculated without
age-weighting and with a discount rate of 3%. When
DALYs were not discounted, the ICER value of DhP
compared to “do-nothing” in the deterministic analysis
decreased from US$ 12.33 to 10.80 per DALY averted.
Age-weighting assigns different values to time lived at
different ages and when it was applied the ICER in-
creased from US$ 12.33 to 18.00 per DALY averted.
None of these choices of method had any influence on
the conclusions.
Discussion
This study has shown that DhP is a cost-effective anti-




Figure 2 Incremental cost-effectiveness scatter plot DhP versus AL. Key: The dots represent incremental cost-effect pairs for DhP versus AL
for 10,000 Monte Carlo simulations. The dotted line represents a willingness-to-pay threshold of US$ 150 per DALY averted.
Base-case Scenario
Figure 3 Cost-effectiveness acceptability curves.
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Figure 4 Sensitivity of ICER to variations in the compliance rates for DhP.
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This finding is higher than the US$ 6.23 per DALY
averted that was predicted by the Committee on the
Economics of Anti-malarial Drugs, which compared
ACT with “do-nothing”, from the provider’s perspective
[40]. The ICER is well below all common rules of thumb
for cost-effectiveness, including the GDP per capita for
each DALY averted recommended by the WHO [59] and
the US$ 150 per DALY averted suggested for low- and
middle-income countries [55]. Therefore, adequate and
timely provision of DhP can be considered a highly cost-
effective treatment for uncomplicated malaria.
DhP is currently more expensive than AL and hence
any decision to adopt it nationwide as a first-line drug
will have significant budget implications. However, DhP
has two major advantages over AL that make it an at-
tractive weapon in the fight against malaria. Firstly, it
has a relatively simple once-a-day, three-day dosage regi-
men and a bioavailability that does not require fat-rich
meals [37]. This is likely to increase adherence to treat-
ment, which will minimize wastage and improve thera-
peutic outcomes. Secondly, DhP has a long eliminationhalf-life, which may give it a prolonged post-treatment
prophylactic effect that would help to reduce future
costs from recurrent infections [18].
In the base-case analysis, DhP was a dominant strategy
based on the assumption that it has a compliance rate
higher than that of AL; unfortunately, this has not been
documented in clinical practice. Since the two drugs
have similar safety profiles [13], and taking into account
the complex dosage regimen and the pill burden of AL,
it is unlikely that the compliance rate for DhP will be
lower than that of AL. In addition, the prolonged
post-treatment prophylactic effect of DhP, which we did
not consider in the analysis, would increase its cost-
effectiveness. A recent study has shown that DhP was
strongly dominant over AL with a probability of 90%, by
modelling the differences in post-treatment prophylactic
effect of the two drugs [18].
DhP has received regulatory approval from the Euro-
pean Medicines Agency (EMA) and can now be pro-
cured with donor funds [60], at an affordable maximum
price of less than US$ 1 per dose [29]. Sigma-Tau, the
manufacturer of DhP (Eurartesim®), in collaboration with
Figure 5 ICER tornado diagram of DhP compared to “do-nothing”. Key: *Incidence rates as percentage of febrile episodes. Unless otherwise
indicated, the numbers in the brackets represent probabilities
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http://www.malariajournal.com/content/13/1/363Medicine for Malaria Venture, are also developing a
new water-dispersible formulation for children under
the age of five years [61]. With generic competition,
the price of DhP is likely to decrease even further over
the coming years.
Even though DhP is a very promising long-acting
anti-malarial drug, concerns have been raised about its
residual drug levels as a potential risk for the emer-
gence of resistance, especially in high transmission
areas [62,63]. A reliable surveillance system is there-
fore needed to monitor its therapeutic efficacy [13].
Several studies have also shown that the administered
dosage and the resulting plasma concentrations are the
most important predictors of treatment failures in children
treated with DhP [64,65]. Thus, malaria experts have sug-
gested increasing the minimum dosage of piperaquine rec-
ommended by the WHO from 48 to 59 mg/kg in order to
achieve desirable plasma concentrations [64].
Presumptive treatments and non-adherence to nega-
tive test results is another common challenge facing thedeployment of expensive drugs like DhP in endemic
countries. Studies in Tanzania have shown that malaria
is highly over diagnosed and non-adherence to negative
test results may be as high as 53% [56]. The WHO’s mal-
aria report of 2011 showed that perfect compliance with
negative test results would save US$ 68 million by elim-
inating the unnecessary use of ACT in the public sector
in Africa [66].
Limitations
The study used the two-week self-reported prevalence of
fever from a national survey to estimate the weekly inci-
dence rates of febrile episodes in children [50]. This
approach can overestimate or underestimate the actual
incidence rates given the seasonal variation of fever epi-
sodes and when counting is not precise due to the over-
lapping of fevers during the two-week period. This is,
however, a preferred approach in the absence of system-
atically collected data about the annual incidence rates
of febrile episodes [66].
Figure 6 Two-way sensitivity analysis of compliance rates for DhP and AL.
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low-income countries because resource use and atten-
dances at specific departments are not always properly
documented. Therefore, we did not include costs for
consumables, such as cannulas, syringes, cotton wool
and infusion sets. It was also very challenging to allocate
overhead costs to service departments, and this forced
us to use weighted factors. It was also difficult to ad-
equately calculate unit costs for laboratory and phar-
macy services because attendances at these units were
not properly recorded. Therefore, the estimated unit
costs may have underestimated the actual treatment
costs for uncomplicated and severe malaria.
The study was conducted from a provider’s perspec-
tive without including a more comprehensive societal
perspective. Unlike DhP, the use of AL is associated
with greater costs due to the requirement for fat-rich
meals to optimize its bioavailability. A societal per-
spective may, therefore, increase treatment costs
relatively more for AL, thus favouring DhP in the cost-
effectiveness analysis.The study was focused on health losses due to malaria
only, therefore, DALYs lost from the associated co-
morbidities of severe malaria such as anemia, convul-
sions and long-term neurological injury were not
included in the model. Their inclusion would have
favoured DhP in the cost-effectiveness analysis, because
it is relatively more effective than AL due to its high ef-
ficacy and compliance rates.Generalizability
The study used AL, which is the current first-line anti-
malarial drug against uncomplicated malaria in many
malaria-endemic countries, as a comparator. The drug
prices also include freight and insurance charges as well
as local administrative costs, which to a large extent
accommodate uncertainties in supplier prices. Given that
the results were robust to plausible variations in all
the key parameters, they are likely to be relatively
generalizable to other settings with similar healthcare
infrastructures and malaria epidemiology.
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DhP is a very cost-effective anti-malarial drug. The find-
ings support its use as an alternative first-line drug for
treating uncomplicated malaria in children in Tanzania
and other sub-Saharan African countries with similar
healthcare infrastructures and malaria epidemiology. A
number of countries in malaria-endemic areas are cur-
rently considering the adoption of DhP in their malaria
treatment guidelines. Therefore, policy-makers in these
countries should employ this evidence in order to make
informed decisions about allocating their limited re-
sources to competing healthcare interventions.
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